BACKGROUND/ PURPOSE: The aim of this study was to retrospectively analyze the clinical presentation, histology, treatment, and outcomes of children with vaginal tumors who were treated at a single institution. METHODS: A retrospective review of medical records and pathologic materials of all children with vaginal tumors treated at St Jude Children's Research Hospital between 1970 and 2009 was conducted. RESULTS: Eighteen patients (median age, 3.7 years; range, 0.1-15 years) were identified. Three different histologies were found: rhabdomyosarcoma (RMS; n = 13), germ cell tumor (n = 3), and clear cell adenocarcinoma (n = 2). Bleeding or blood-tinged discharge was the most common clinical presentation (66%), followed by a protruding mass (39%). Vaginal and uterine salvage was 44.4% (8 of 18 patients). Thirteen patients (72.2%) remain disease-free, with a median follow-up of 23.2 years (range, 2-39 years). Four patients (22.2%) died of disease progression (1 RMS, 2 germ cell tumor, and 1 clear cell adenocarcinoma), and 1 patient with RMS died of colon cancer 12 years after the primary diagnosis had been made. CONCLUSIONS: Vaginal tumors are extremely rare in the pediatric population. Early recognition of symptoms like bleeding and a protruding vaginal mass may prevent morbidity and mortality. Our findings confirm the good prognosis of vaginal RMS.
BACKGROUND/ PURPOSE: The aim of this study was to retrospectively analyze the clinical presentation, histology, treatment, and outcomes of children with vaginal tumors who were treated at a single institution. METHODS: A retrospective review of medical records and pathologic materials of all children with vaginal tumors treated at St Jude Children's Research Hospital between 1970 and 2009 was conducted. RESULTS: Eighteen patients (median age, 3.7 years; range, 0.1-15 years) were identified. Three different histologies were found: rhabdomyosarcoma (RMS; n = 13), germ cell tumor (n = 3), and clear cell adenocarcinoma (n = 2). Bleeding or blood-tinged discharge was the most common clinical presentation (66%), followed by a protruding mass (39%). Vaginal and uterine salvage was 44.4% (8 of 18 patients). Thirteen patients (72.2%) remain disease-free, with a median follow-up of 23.2 years (range, 2-39 years). Four patients (22.2%) died of disease progression (1 RMS, 2 germ cell tumor, and 1 clear cell adenocarcinoma), and 1 patient with RMS died of colon cancer 12 years after the primary diagnosis had been made. CONCLUSIONS:Vaginal tumors are extremely rare in the pediatric population. Early recognition of symptoms like bleeding and a protruding vaginal mass may prevent morbidity and mortality. Our findings confirm the good prognosis of vaginal RMS.
Authors: P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: W M Crist; L Garnsey; M S Beltangady; E Gehan; F Ruymann; B Webber; D M Hays; M Wharam; H M Maurer Journal: J Clin Oncol Date: 1990-03 Impact factor: 44.544
Authors: R J Andrassy; D M Hays; R B Raney; E S Wiener; W Lawrence; T E Lobe; C A Corpron; M Smith; H M Maurer Journal: J Pediatr Surg Date: 1995-07 Impact factor: 2.545
Authors: W A Newton; E A Gehan; B L Webber; H B Marsden; A J van Unnik; A B Hamoudi; M G Tsokos; H Shimada; D Harms; D Schmidt Journal: Cancer Date: 1995-09-15 Impact factor: 6.860
Authors: A Atra; H C Ward; K Aitken; M Boyle; C Dicks-Mireaux; P G Duffy; C D Mitchell; P N Plowman; P G Ransley; J Pritchard Journal: Br J Cancer Date: 1994-11 Impact factor: 7.640
Authors: Anisa W Mburu; Peter M Itsura; Elkanah O Orang'o; Philliph K Tonui; Elly B Odongo; Afrin F Shaffi; Hellen N Muliro; Thomas N Achia; Allan L Covens; Barry P Rosen Journal: Gynecol Oncol Rep Date: 2022-03-10